KLTO — Klotho Neurosciences, Inc.

KLTO closed at $0.5242 (+0.81%) on Mar 11, 2026. Active shelf registration (S-3, Jul 2025). Float: 64.0M shares. Latest SEC filing: 8-K on Oct 2, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for KLTO in the TickerWise workspace.

Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 3
• Website: https://klothoneuro.com

Latest SEC filings for KLTO

• 2026-10-028-K
• 2026-09-288-K
• 2026-09-28424B5
• 2026-09-23424B5
• 2026-09-23424B5
• 2026-09-238-K
• 2026-09-118-K
• 2026-09-048-K
• 2026-08-27424B5
• 2026-08-278-K

Related companies

• VRTX — Vertex Pharmaceuticals Incorporated
• MRNA — Moderna, Inc.
• REGN — Regeneron Pharmaceuticals, Inc.
• ARGX — argenx SE
• ALNY — Alnylam Pharmaceuticals, Inc.
• INSM — Insmed Incorporated
• RVMD — Revolution Medicines, Inc.
• UTHR — United Therapeutics Corporation

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.